Company intelligence / Profile preview

Atterx Biotherapeutics

Madison, Wisconsin, United Statesatterx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Atterx is developing novel products to prevent and treat antibiotic-resistant bacterial infections. Their lead product C-1205 uses bacterial interference technology to prevent catheter-associated UTIs and has received FDA approval for a Phase I trial. Their GN-4474 product is in preclinical development for gram-negative bacterial infections.

Therapeutic areas: Infectious Diseases
Modalities: Bacterial interference technologyBacterial conjugation
Industry: Biotech

Drug pipeline

2 assets

GN-4474

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Atterx Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atterx Biotherapeutics.

Explore the full profile